Revenue up 5.2% but PBT fell 13.5% as segment margins compressed sharply

The effective tax rate was unchanged at 27.8% in both periods, so NPAT fell at the same rate, to NZD 33.8 million.

The sharpest deterioration was in the NZ market genetics segment, where a 9.1% revenue gain to NZD 116.5 million was accompanied by a fall in derived gross margin from 65.8% to 46.1%. The testing segment nearly doubled its revenue to NZD 36.6 million — partly reflecting the segment presentation change flagged in the prior comparable amendment — but its derived margin collapsed from 47.4% to 12.7%. Farm software revenue was flat at NZD 28.7 million while its margin fell from 74.5% to 60.4%.

Operating cash flow rose modestly to NZD 12.2 million from NZD 11.4 million. The balance sheet carries no debt and cash improved to NZD 34.7 million.

Every comparable segment saw derived gross margin fall materially in HY26. Because NZ market genetics accounts for roughly 60% of revenue, its margin drop from 65.8% to 46.1% alone accounts for the bulk of the PBT decline despite a strong revenue number. This means LIC converted a 5.2% revenue gain into a 13.5% profit decline — a pattern that signals cost inflation or product-mix shifts are outpacing pricing and volume.

The testing segment's revenue near-doubling warrants close scrutiny. The prior comparable period result carries an amendment flag, and the testing segment's revenue of NZD 17.7 million in HY25 rising to NZD 36.6 million in HY26 is an unusually large step. Whether this reflects organic volume growth, a segment reclassification, or a prior-period restatement is not fully clear from the supplied materials. If the HY25 testing figure was understated in the original filing, some of the apparent margin collapse in testing is a comparison artefact rather than economic deterioration.

Seasonality makes the first half the profit half. In FY25, the first half generated 127.5% of full-year NPAT, implying a loss in the second half. With HY26 NPAT already 13.5% below the prior first half, the full-year outcome will be sensitive to whether the second-half pattern repeats. Management commentary references R&D investment at 8% of revenue as a deliberate strategic commitment, which is likely a driver of second-half cost drag.

Based on FY25 seasonality, first-half profit represents the majority of the full-year result, and LIC's second half has historically produced a net loss at the NPAT level. With a weaker first half in HY26, the full-year NPAT trajectory is below the FY25 outcome absent a meaningful improvement in second-half conditions.

Management commentary frames the revenue growth as positioning LIC well for the future, highlighting sexed semen volume, animal health, and R&D investment. The 8% of revenue directed to R&D (up 6%) is consistent with elevated cost pressures being partly strategic. What the release does not address is whether the margin compression in genetics and testing is expected to reverse in the second half or persist into FY27.

However, the profit quality is weaker. The wide divergence between revenue growth and PBT growth — 5.2% versus -13.5% — is driven by cost increases that appear across all segments simultaneously, which is harder to characterise as timing-driven or one-off.

Operating cash flow of NZD 12.2 million is low relative to NPAT of NZD 33.8 million, reflecting the normal first-half pattern where receivables are high at the close of the mating season. Trade debtors of NZD 88.5 million represent 45% of half-year revenue. The no-debt balance sheet and NZD 34.7 million cash position are genuinely strong and provide financial flexibility, but they do not offset the earnings-quality concern from compressed operating margins.

This briefing cannot assess the underlying cost structure at the product or channel level, the impact of the HY25 amendment on segment comparability, or the degree to which HY26 margin compression is structural versus reversible.